Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US firms Formation Bio and OpenAI to develop customized artificial intelligence (AI) models designed to expedite drug development. While the financial specifics of the agreement were not disclosed, the partnership signifies Sanofi’s strategic commitment to leveraging AI at an unprecedented scale within the pharmaceutical industry.
Under this alliance, Sanofi will contribute its proprietary data to train the advanced AI software, marking a significant step towards becoming the first pharmaceutical company to implement AI on a large scale. The collaboration holds the promise of revolutionizing drug discovery and development processes by harnessing the power of AI and machine learning.- Flcube.com
